ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Male and female, age >= 18 years and <= 80 years, with a diagnosis of type 2 diabetes made at least 6 months prior to study entry, with hemoglobin A1C 7.5-10%
- Currently treated with 2 or more oral antidiabetic agents (sulfonylureas, metformin, and/or thiazolidinediones)
- Type 1 diabetes
- Smoking within the past 6 months or significant pulmonary diseases
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Fresno, California
- San Antonio, Texas
- Birmingham, Alabama
- Los Angeles, California
- New Britain, Connecticut
- Norwalk, Connecticut
- Hollywood, Florida
- Atlanta, Georgia
- Boise, Idaho
- Hayden, Idaho
- Baton Rouge, Louisiana
- Boston, Massachusetts
- Albany, New York
- Syracuse, New York
- Dallas, Texas
- El Paso, Texas
- San Antonio, Texas
- Bennington, Vermont
- Chandler, Arizona
- Mesa, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Tempe, Arizona
- Los Angeles, California
- San Diego, California
- Colorado Springs, Colorado
- Newark, Delaware
- Wilmington, Delaware
- Washington, District of Columbia
- Jacksonville, Florida
- Jacksonville, Florida
- Hayden, Idaho
- Nampa, Idaho
- Gurnee, Illinois
- Elkton, Maryland
- Detroit, Michigan
- Minneapolis, Minnesota
- St. Louis, Missouri
- Omaha, Nebraska
- Margate City, New Jersey
- Santa Fe, New Mexico
- New York, New York
- Morehead City, North Carolina
- Salisbury, North Carolina
- Statesville, North Carolina
- Winston-Salem, North Carolina
- Cincinnati, Ohio
- Portland, Oregon
- Portland, Oregon
- Orangeburg, South Carolina
- Simpsonville, South Carolina
- Arlington, Texas
- Dallas, Texas
- Madisonville, Texas
- San Antonio, Texas
- Bennington, Vermont
- Virginia Beach, Virginia
- Spokane, Washington
- Tacoma, Washington
- Milwaukee, Wisconsin
- Birmingham, Alabama
- Gilbert, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Jonesboro, Arkansas
- Little Rock, Arkansas
- Carmichael, California
- Chula Vista, California
- Fair Oaks, California
- Los Angeles, California
- National City, California
- Paramount, California
- Roseville, California
- Sacramento, California
- DeFuniak Springs, Florida
- Destin, Florida
- Jacksonville, Florida
- New Port Richey, Florida
- New Port Richey, Florida
- Palm Harbor, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Conyers, Georgia
- Chicago, Illinois
- Skokie, Illinois
- Skokie, Illinois
- Wheeling, Illinois
- Lexington, Kentucky
- Lexington, Kentucky
- Brockton, Massachusetts
- Worcester, Massachusetts
- Ann Arbor, Michigan
- Canton, Michigan
- Flint, Michigan
- Biloxi, Mississippi
- Picayune, Mississippi
- St. Louis, Missouri
- Omaha, Nebraska
- Las Vegas, Nevada
- Las Vegas, Nevada
- Las Vegas, Nevada
- Trenton, New Jersey
- Cary, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Marion, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Carnegie, Pennsylvania
- East Providence, Rhode Island
- Bartlett, Tennessee
- Collierville, Tennessee
- Kingsport, Tennessee
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Irving, Texas
- San Antonio, Texas
- San Antonio, Texas
- Richmond, Virginia
- Virginia Beach, Virginia
- Milwaukee, Wisconsin
- Bogota, Cundinamarca
- Bogota, Cundinamarca
- Floridablanca, Santander
- Berlin,
- Giengen,
- Hamburg,
- Muenchen,
- Roma,
- Santiago de Compostela, La Coruña
- Alcala de Henares, Madrid
- Valencia,
- Valencia,
- Goteborg,
- Malmo,
- Stockholm,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | US Inhaled Insulin Dose Titration Study | |||
Official Title ICMJE | A Randomized, Open-Label, Multicenter Study Assessing the Effects of Forced Exubera Dose Titration on Glycemic Control in Patients With Suboptimally Controlled Type 2 Diabetes on Two or More Oral Antidiabetic Agents | |||
Brief Summary | This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in the study can reach the target Hemoglobin A1C levels (7% or less) that have been set by the American Diabetes Association (ADA). Target goals should be achieved by adjusting the Exubera dose either weekly or twice weekly. Patients will also receive nutritional counseling and diabetes education as part of the study. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Diabetes Mellitus, Type 2 | |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 120 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | March 2007 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 80 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00246623 | |||
Other Study ID Numbers ICMJE | A2171067 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Sanofi | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | May 2007 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |